WSJ -- Eli Lilly & Co.'s first-quarter earnings fell 15% amid higher operating expenses and restructuring costs despite the pharmaceutical giant’s revenue benefiting from higher prices. “Growth in international markets and the strong performance of Cymbalta, Alimta and our animal-health business drove volume-based revenue growth of 6%, despite a significant decline in Gemzar sales due to generic competition,” Chairman and Chief Executive John Lechleiter said. He also said the company’s restructuring plans are on track, along with plans to have at least 10 potential new drugs in Phase 3 development by the end of the year.
